venBio Partners LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), venBio Partners LLC reported 6 stock positions worth $231.5 million. Its top holding was Pharvaris (PHVS) at 34.8% of the portfolio, followed by Alx Oncology (ALXO, 25.3%) and Alumis (ALMS, 16.2%). Compared with Q1 2024, it opened 1 new position and reduced 1. The biggest buy was a new position in Alumis (ALMS) and the biggest sale Elevation Oncology (ELEV, shares −10%).
- Most Recent 13F
- Q2 2026
- Location
- SAN FRANCISCO, CA
- CIK
- 0001776382
- Portfolio Value
- $231.5M (Q2 2024)
- SEC Filing
- 0000905148-24-002220 ↗ filed Aug 14, 2024
Holdings Value
Holdings 6 stocks · $231.5M
| PHVS Pharvaris NV | 34.83% | 4,289,304 | $80.6M | No change |
| ALXO Alx Oncology Holdings Inc. | 25.26% | 9,699,925 | $58.5M | No change |
| ALMS Alumis Inc. | 16.23% | 2,826,048 | $37.6M | New |
| HRMY Harmony Biosciences Holdings | 13.49% | 1,035,396 | $31.2M | No change |
| SLRN Acelyrin Inc. | 7.34% | 3,852,470 | $17.0M | No change |
| ELEV Elevation Oncology Inc. | 2.84% | 2,434,255 | $6.6M | Reduce -9.7% |
Portfolio Sells Q1 2024 → Q2 2024
| ELEV Elevation Oncology Inc. | Reduce -9.7% | 2.84% | −2.07 |
Portfolio Buys Q1 2024 → Q2 2024
| ALMS Alumis Inc. | New | 16.23% | +16.23 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 7 | $519.4M | PHVS, PBLS, ALMS, ACHV, ALXO |
| Q1 2026 | 6 | $280.6M | PHVS, ALMS, ALXO, HRMY, LYEL |
| Q4 2025 | 6 | $216.3M | PHVS, ALMS, HRMY, ALXO, LYEL |
| Q3 2025 | 6 | $176.4M | PHVS, ALMS, ALXO, HRMY, LYEL |
| Q2 2025 | 6 | $114.8M | PHVS, HRMY, ALMS, LYEL, ALXO |
| Q1 2025 | 7 | $123.6M | PHVS, ALMS, HRMY, SLRN, ALXO |
| Q4 2024 | 7 | $170.7M | PHVS, ALMS, HRMY, ALXO, ARTV |
| Q3 2024 | 6 | $194.3M | PHVS, ALMS, HRMY, ARTV, SLRN |
| Q2 2024 | 6 | $231.5M | PHVS, ALXO, ALMS, HRMY, SLRN |
| Q1 2024 | 5 | $281.9M | ALXO, PHVS, HRMY, SLRN, ELEV |